Mepolizumab Reduces COPD Flares in Eosinophilic Patients
-
By
May 30, 2025
-
3 min
-
1
Mepolizumab, targeting IL-5, reduced COPD exacerbation frequency and emergency visits/hospitalizations.
-
2
Study included 804 COPD patients with elevated eosinophil levels.
-
3
Participants receiving mepolizumab showed a 21% relative reduction in exacerbation rate.
-
4
Time to first exacerbation was longer with mepolizumab.
-
5
No significant differences in patient-reported outcomes were observed.
-
6
Adverse events were reported in 74% of the mepolizumab group and 77% of the placebo group.
-
7
Common adverse events with mepolizumab included worsening COPD and SARS-CoV-2 infection.
-
A phase III trial revealed that mepolizumab, a monoclonal antibody targeting interleukin-5, reduced exacerbation frequency in patients with chronic obstructive pulmonary disease (COPD) and elevated eosinophil levels. The study enrolled 804 participants and demonstrated a 21% relative reduction in exacerbation rate with mepolizumab compared to placebo, along with longer time to first exacerbation and fewer emergency visits or hospitalizations.
-
1
Mepolizumab, targeting IL-5, reduced COPD exacerbation frequency and emergency visits/hospitalizations.
-
2
Study included 804 COPD patients with elevated eosinophil levels.
-
3
Participants receiving mepolizumab showed a 21% relative reduction in exacerbation rate.
-
4
Time to first exacerbation was longer with mepolizumab.
-
5
No significant differences in patient-reported outcomes were observed.
-
6
Adverse events were reported in 74% of the mepolizumab group and 77% of the placebo group.
-
7
Common adverse events with mepolizumab included worsening COPD and SARS-CoV-2 infection.
Listen Tab content
